Riverhead Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Riverhead Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$151K	Buy	11,673 +300	+3%	+$3.62K	0.01%	1224
2019 Q2	$142K	Hold	11,373	–	–	0.01%	1261
2019 Q1	$165K	Buy	11,373 +100	+0.9%	+$1.28K	0.01%	1203
2018 Q4	$124K	Buy	11,273 +3,400	+43%	+$47.3K	0.01%	1241
2018 Q3	$207K	Buy	7,873 +1,100	+16%	+$29.7K	0.01%	1195
2018 Q2	$139K	Hold	6,773	–	–	0.01%	1241
2018 Q1	$123K	Hold	6,773	–	–	0.01%	1276
2017 Q4	$94K	Buy	6,773 +500	+8%	+$6.76K	﹤0.01%	1363
2017 Q3	$116K	Buy	6,273 +1,879	+43%	+$31.4K	0.01%	1235
2017 Q2	$74K	Buy	4,394 +2,294	+109%	+$34.9K	﹤0.01%	1323
2017 Q1	$28K	Sell	2,100 -400	-16%	-$6.26K	﹤0.01%	1416
2016 Q4	$38K	Hold	2,500	–	–	﹤0.01%	1304
2016 Q3	$29K	Sell	2,500 -2,975	-54%	-$35K	﹤0.01%	1321
2016 Q2	$1.04M	Sell	5,475 -6,900	-56%	-$71.2K	0.03%	424
2016 Q1	$114K	Sell	12,375 -4,125	-25%	-$44.4K	﹤0.01%	1325
2015 Q4	$245K	Buy	16,500 +11,700	+244%	+$196K	﹤0.01%	1209
2015 Q3	$79K	Buy	+4,800	New	+$98.3K	﹤0.01%	1171

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Riverhead Capital Management's MNTA Position: Q3 2019 in Review

Riverhead Capital Management increased its Momenta Pharmaceuticals, Inc. (MNTA) stake by 2.6% in Q3 2019, buying an estimated $3.62K and bringing the position to 11,673 shares worth $151K. The position accounts for 0.01% of the portfolio, ranked #1224.

Riverhead Capital Management first reported a position in MNTA in Q3 2015 and has held it in 17 quarters since. The position peaked at $1.04M in Q2 2016. 154 funds tracked by Wall St. Rank hold MNTA as of Q3 2019.

Riverhead Capital Management held 11,673 shares of Momenta Pharmaceuticals, Inc. worth $151K as of Q3 2019.
Riverhead Capital Management bought 300 Momenta Pharmaceuticals, Inc. shares in Q3 2019, an estimated $3.62K.
Momenta Pharmaceuticals, Inc. made up 0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1224 holding.
Riverhead Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2015 and has held it in 17 quarters since.
Riverhead Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $1.04M in Q2 2016.
154 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.